No Data
No Data
No Data
No Data
No Data
Theriva Biologics Files Mixed-Securities Shelf
Theriva Biologics Files Mixed-Securities Shelf
BenzingaMay 3 05:21
Theriva Biologics To Discuss The Trial Design For VIRAGE - A Phase 2b Clinical Study Of Systemically Administered VCN-01 In Combination With Chemotherapy In Pancreatic Ductal Adenocarcinoma At The 2024 ASCO Annual Meeting
Theriva Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that, based on th
BenzingaApr 25 20:34
Theriva Biologics Disclosed Positive Topline Data From Investigator Sponsored Phase 1 Trial Of Intravitreal VCN-01 In Pediatric Patients With Refractory Retinoblastoma
Theriva Biologics Disclosed Positive Topline Data From Investigator Sponsored Phase 1 Trial Of Intravitreal VCN-01 In Pediatric Patients With Refractory Retinoblastoma
BenzingaApr 23 20:40
Theriva Biologics' VCN-01 Shows Promise in Pediatric Cancer Trial
TipRanksApr 23 19:12
Theriva Biologics Reports Breakthrough in Pancreatic Cancer Therapy
TipRanksApr 23 04:53
Theriva Biologics To Present Preclinical Data For Potential Synergy Of VCN-01 And First-Line Pancreatic Cancer Chemotherapy Regimens At American Society For Cell And Gene Therapy 27th Annual Meeting
– Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft–– The observed synergy emphasizes VCN-01's pote
BenzingaApr 23 04:37
No Data
No Data